Every material Form 8-K ClearPoint Neuro, Inc. has filed with the SEC since May 21, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
ClearPoint Neuro reported third-quarter 2026 revenue of $12.1 million, up 36% from $8.9 million a year earlier, with growth led by the recently acquired IRRA flow products. The net loss widened to $7.5 million, or $0.24 per share, from $5.9 million, or $0.21 per share, as operating expenses rose 23% and gross margin fell to 58% from 63%. The company now estimates 2026 revenue of $48.0 million to $50.0 million.
Q3 2026 revenue was $12.1 million, up 36% from $8.9 million; neurosurgery navigation and therapy revenue rose 59% to $5.4 million.
Net loss was $7.5 million ($0.24 per share) versus $5.9 million ($0.21 per share) in Q3 2025; operating expenses rose to $13.4 million from $10.9 million.
Gross margin was 58% compared with 63%, which the company attributed to overhead at ClearPoint Advanced Laboratories and higher amortization of acquired intangible assets.
Cash and cash equivalents were $46.2 million at September 30, 2026, including $22.0 million in net proceeds from the at-the-market equity offering program.
ClearPoint Neuro reported second-quarter 2026 revenue of $10.9 million, up 18% from a year earlier, helped by the IRRA flow product, while its net loss more than doubled to $11.3 million. The company also set 2026 revenue guidance at $48.0 million to $52.0 million and said it is shifting spending toward clinical capacity and preclinical services, which shareholders should weigh against the higher losses and lower cash balance.
Q2 2026 revenue was $10.9 million, up from $9.2 million; biologics and drug delivery revenue fell 15% to $4.0 million.
Net loss was $11.3 million, or $0.38 per share, versus $5.8 million, or $0.21 per share, a year earlier.
Operating expenses rose 51% to $17.0 million, and cash and cash equivalents were $29.4 million at June 30, 2026, down from $45.9 million at December 31, 2025.
The company's 2026 revenue guidance is $48.0 million to $52.0 million, described as an adjustment to its revised priorities.
At its annual meeting on May 20, 2026, ClearPoint Neuro stockholders approved the Seventh Amended and Restated 2013 Incentive Compensation Plan, elected seven directors to serve until the 2027 annual meeting, and ratified Cherry Bekaert LLP as auditor for 2026. The Board also confirmed R. John Fletcher as Chairman and set new committee memberships, so shareholders now have the plan's terms and an updated board structure in place.
Incentive plan approved with 7,517,634 votes for, 1,793,261 against and 495,788 abstentions.
All seven director nominees elected; Joseph M. Burnett received 9,686,224 votes for and 120,459 withheld.
Advisory vote on executive compensation: 8,825,126 for, 442,728 against and 538,829 abstentions.
R. John Fletcher confirmed as Board Chairman; Lynnette C. Fallon chairs the Audit Committee and B. Kristine Johnson chairs the Compensation Committee.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ClearPoint Neuro, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →